Загрузка...
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
BACKGROUND: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can occur even in patients with seeming clinical remission. This lead to the con...
Сохранить в:
| Опубликовано в: : | BMC Gastroenterol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4683713/ https://ncbi.nlm.nih.gov/pubmed/26678147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0408-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|